Biologics development program
This program is developing new ‘biologics’ to prevent or treat COVID-19. Biologics are medicines that mimic naturally occurring proteins such as antibodies – immune proteins that fight infection. The program is searching for new biologics medicines that prevent SARS-CoV-2 from binding to human lung cells – the first step in the virus infection cycle. Antibodies are already in clinical use for diseases such as cancer and inflammatory and autoimmune conditions and have also been used for the treatment and prevention of other viruses such as Ebola and HIV.
Project collaborators
Funders
- Medical Research Future Fund
- Paul Ramsay Foundation